(Q46225464)

20 December 2017

title

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. (English)

1 reference

20 December 2017

1 reference

Francesco Ceci

5

0 references

John J Sunderland

object named as

John Sunderland

14

0 references

Stefano Fanti

object named as

Stefano Fanti

17

0 references

author name string

Wolfgang P Fendler

1

1 reference

20 December 2017

Matthias Eiber

2

1 reference

20 December 2017

Mohsen Beheshti

3

1 reference

20 December 2017

Jamshed Bomanji

4

1 reference

20 December 2017

Steven Cho

6

1 reference

20 December 2017

Frederik Giesel

7

1 reference

20 December 2017

Uwe Haberkorn

8

1 reference

20 December 2017

Thomas A Hope

9

1 reference

20 December 2017

Klaus Kopka

10

1 reference

20 December 2017

Bernd J Krause

11

1 reference

20 December 2017

Felix M Mottaghy

12

1 reference

20 December 2017

Heiko Schöder

13

1 reference

20 December 2017

Simon Wan

15

1 reference

20 December 2017

Hans-Jürgen Wester

16

1 reference

20 December 2017

Ken Herrmann

18

1 reference

20 December 2017

publication date

10 March 2017

1 reference

20 December 2017

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

20 December 2017

volume

44

1 reference

20 December 2017

issue

6

1 reference

20 December 2017

page(s)

1014-1024

1 reference

20 December 2017

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

(68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Acceptance testing for nuclear medicine instrumentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-017-3670-Z

Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis

21 January 2018

1 reference

12 December 2020

Neuroendocrine differentiation of prostate cancer: a review

1 reference

12 December 2020

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer

1 reference

12 December 2020

Prostate-specific membrane antigen expression in normal and malignant human tissues

1 reference

12 December 2020

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

1 reference

12 December 2020

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.

1 reference

12 December 2020

Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

1 reference

12 December 2020

Prostate-specific membrane antigen is produced in tumor-associated neovasculature

1 reference

12 December 2020

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy

1 reference

12 December 2020

Understanding the standardized uptake value, its methods, and implications for usage.

1 reference

12 December 2020

[(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice

1 reference

12 December 2020

10.1007/S00259-017-3670-Z

Identifiers

DOI

1 reference

20 December 2017

release_f3liyi4kevegdhjvu6h3q3jx4m

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f3liyi4kevegdhjvu6h3q3jx4m

24 November 2022

mapped directly with Wikidata item

1 reference

20 December 2017